Difficult to read

12/02/20 -"Akzo’s FY figures leave certain room for interpretation as we really need to see the annual report. EBITDA is the central metric for our valuation and this line could be seen at various levels. ..."

Executive summary
Conflict of interest

Pages

Language

English

Published on

12/02/20

Download

You may also be interested by these reports :

28/08/26

Wacker Chemie

2026: The increase is largely attributed to lower operational expenses in Q2 resulting in an upward revision of our estimate for adj. EBIT to €153m ...

28/08/26

Brenntag

We are raising our FY26 EPS estimate by 12%, mainly reflecting the stronger operating earnings outlook following the Q2 performance and the upgrade ...

27/08/26

Givaudan

Givaudan utilised its Summer Investor Conference to reaffirm its 2030 financial ambitions and refine its strategy under the new CEO. The adjustments ...

25/08/26

Clariant

The decline in EPS is due to a slight increase in shares outstanding.

EXECUTIVE SUMMARY

Updates

Pension Risks

Target & Opinion

Governance & Management

Business & Trends

Graphics : Momentum

Money Making

Graphics : MACD & Volumes

Debt

Graphics : Sensitivities

Valuation

Sector: Performance

DCF

Sector: Key data

NAV/SOTP

Sector: Ratios & Valorisation

Worth knowing

Sector: Peers

Financials

Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking

Trading in corporate shares

Analyst ownership

Advising of corporate (strategy, marketing, debt, etc)

Research paid for by corporate

Provision of corporate access paid for by corporate

Link between and a banking entity

Brokerage activity at AlphaValue

AkzoNobel